Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

Human epidermal growth factor receptor 2 (HER2) tyrosine kinase is overexpressed in 20% of breast cancers and associated with a less favorable prognosis compared to HER2-negative disease. Patients have traditionally been treated with a combination of chemotherapy and HER2-targeted monoclonal antibod...

Full description

Bibliographic Details
Main Authors: Brittney S. Zimmerman, Francisco J. Esteva
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Cancers
Subjects:
HER2
antibody–drug conjugates
breast neoplasms
targeted therapy
trastuzumab deruxtecan
trastuzumab-DM1
Online Access:https://www.mdpi.com/2072-6694/16/4/800

Similar Items

Similar Items